{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:34:03Z","timestamp":1791462843407,"version":"4.3.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Advanced adrenocortical carcinoma (ACC) is an aggressive disease with poor prognosis, and the current therapeutic options, such as mitotane or platinum-based chemotherapy regimens, often offer limited efficacy. Here, we present the first report, to the author's knowledge, of metastatic ACC with positive octreoscan scintigraphy that was successfully treated with octreotide long-acting release (LAR). A patient with metastatic ACC who showed poor tolerance to mitotane received octreotide LAR because of positive octreoscan scintigraphy. She obtained major partial response to the somatostatin analog. Interestingly, the expression of somatostatin receptor 2 from the previous local recurrence lesion was negative. The next-generation sequencing-based circulating tumor DNA analysis in the patient was performed and failed to identify any alterations. These findings suggest that octreotide LAR may be a good option for the treatment of metastatic ACC in selected patients.<\/jats:p>","DOI":"10.1634\/theoncologist.2018-0855","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T19:19:06Z","timestamp":1557429546000},"page":"e793-e797","source":"Crossref","is-referenced-by-count":5,"title":["Metastatic Adrenal Cortical Carcinoma Responding to Octreotide: A Case Report"],"prefix":"10.1093","volume":"24","author":[{"given":"Xiang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Zhu","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine and Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"2021122507523101700_R1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"2021122507523101700_R2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fcell.2015.00045","article-title":"Adrenocortical carcinoma(ACC): Diagnosis, prognosis, and treatment","volume":"3","author":"Lib\u00e9","year":"2015","journal-title":"Front Cell Dev Biol"},{"key":"2021122507523101700_R3","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122507523101700_R4","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122507523101700_R5","article-title":"Detection of rare mutations in CtDNA using next generation sequencing","volume":"126","author":"Lv","year":"2017","journal-title":"J Vis Exp"},{"key":"2021122507523101700_R6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-019-0939-9","article-title":"Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol cancer"},{"key":"2021122507523101700_R7","doi-asserted-by":"crossref","DOI":"10.1002\/1878-0261.12456","article-title":"Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer","author":"Zhou","year":"2019","journal-title":"Mol Oncol."},{"key":"2021122507523101700_R8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","article-title":"The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: A multi-institutional NCI-sponsored trial","volume":"5","author":"Lerario","year":"2014","journal-title":"Horm Cancer"},{"key":"2021122507523101700_R9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122507523101700_R10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/EJE-09-0804","article-title":"Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma","volume":"162","author":"Wortmann","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"2021122507523101700_R11","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O'Sullivan","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122507523101700_R12","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122507523101700_R13","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1210\/jc.2007-2564","article-title":"Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine","volume":"93","author":"Quinkler","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122507523101700_R14","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122507523101700_R15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1677\/ERC-07-0288","article-title":"Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms","volume":"15","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"2021122507523101700_R16","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122507523101700_R17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122507523101700_R18","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1530\/ERC-14-0086","article-title":"Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pNET cultures","volume":"21","author":"Mohamed","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2021122507523101700_R19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1365-2265.2007.03124.x","article-title":"Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours","volume":"68","author":"Unger","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122507523101700_R20","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1007\/BF03346721","article-title":"Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells","volume":"34","author":"Mariniello","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"2021122507523101700_R21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12022-017-9473-8","article-title":"Tissue expression and pharmacological in vitro analyses of mTOR and SSTR pathways in adrenocortical carcinoma","volume":"28","author":"Germano","year":"2017","journal-title":"Endocr Pathol"},{"key":"2021122507523101700_R22","first-page":"39","article-title":"Clinical evaluation of detecting adrenal pheochromocytoma with 99mTc-HYNIC-TOC imaging [in Chinese]","volume":"46","author":"Hongli","year":"2011","journal-title":"Chinese Journal of Medicine"},{"key":"2021122507523101700_R23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/pgmj.71.834.229","article-title":"Secretory symptoms from metastatic adrenal cortical carcinoma responding to octreotide","volume":"71","author":"Pandha","year":"1995","journal-title":"Postgrad Med J"},{"key":"2021122507523101700_R24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0026-0495(96)90072-4","article-title":"Binding properties of somatostatin receptor subtypes","volume":"45","author":"Bruns","year":"1996","journal-title":"Metabolism"},{"key":"2021122507523101700_R25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00428-017-2093-3","article-title":"In liver metastases from small intestinal neuroendocrine tumours, SSTR2A expression is heterogeneous","volume":"470","author":"Charoenpitakchai","year":"2017","journal-title":"Virchows Arch"},{"key":"2021122507523101700_R26","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/modpathol.3800954","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: A proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante","year":"2007","journal-title":"Mod Pathol"},{"key":"2021122507523101700_R27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/gut.38.1.33","article-title":"Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2","volume":"38","author":"John","year":"1996","journal-title":"Gut"},{"key":"2021122507523101700_R28","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s004280100494","article-title":"Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy","volume":"439","author":"Papotti","year":"2001","journal-title":"Virchows Archiv"},{"key":"2021122507523101700_R29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/annonc\/mdp334","article-title":"Somatostatin receptor tissue distribution in lung neuroendocrine tumours: A clinicopathologic and immunohistochemical study of 218 \u2018clinically aggressive\u2019 cases","volume":"21","author":"Righi","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122507523101700_R30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/cen.12775","article-title":"Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores","volume":"83","author":"Diakatou","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122507523101700_R31","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.2008.18.5678","article-title":"Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival","volume":"27","author":"Reynies","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122507523101700_R32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"key":"2021122507523101700_R33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"2021122507523101700_R34","first-page":"923","article-title":"DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer","volume":"102","author":"Jouinot","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122507523101700_R35","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41379-018-0042-6","article-title":"Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas","volume":"31","author":"Vatrano","year":"2018","journal-title":"Mod Pathol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0855","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0855","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/8\/e793\/41922485\/oncolo_24_8_e793.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/8\/e793\/41922485\/oncolo_24_8_e793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:53:43Z","timestamp":1640418823000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/8\/e793\/6439336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,5,9]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0855","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,1]]},"published":{"date-parts":[[2019,5,9]]}}}